Evaluation of synthetic infection-enhancing lipopeptides as adjuvants for a live-attenuated canine distemper virus vaccine administered intra-nasally to ferrets

Vaccine

Volumn 30, Issue 34, 2012, Pages 5073-5080

  Nguyen, D Tien ^a   Ludlow, Martin ^b   van Amerongen, Geert ^a   de Vries, Rory D ^a   Yüksel, Selma ^a   Verburgh, R Joyce ^a   Osterhaus, Albert D M E ^a   Duprex, W Paul ^b   de Swart, Rik L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant; CDV; Lipopeptide; Live attenuated virus vaccine; Paramyxovirus

Indexed keywords

ADJUVANT; DISTEMPER VACCINE; LIPOPEPTIDE; LIVE VACCINE; NEUTRALIZING ANTIBODY; PAM3CSK4; PHCSK4; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CANINE DISTEMPER; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; FERRET; IMMUNE RESPONSE; IMMUNOGENICITY; NASAL LAVAGE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION; VIRUS LOAD; VIRUS RECOMBINANT; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; DISTEMPER; DISTEMPER VIRUS, CANINE; DRUG EVALUATION, PRECLINICAL; FEMALE; FERRETS; LIPOPEPTIDES; LYMPHOCYTES; NEUTRALIZATION TESTS; TRANSFECTION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VERO CELLS; VIRAL LOAD; VIRAL VACCINES;

EID: 84863785142     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.079     Document Type: Article

References (31)

1. Harder T.C., Osterhaus A.D.M.E. Canine distemper virus - a morbillivirus in search of new hosts. Trends Microbiol 1997, 5:120-124.
2. Qiu W., Zheng Y., Zhang S., Fan Q., Liu H., Zhang F., et al. Canine distemper outbreak in rhesus monkeys, China. Emerg Infect Dis 2011, 17:1541-1543.
3. Von Messling V., Milosevic D., Cattaneo R. Tropism illuminated: lymphocyte-based pathways blazed by lethal morbillivirus through the host immune system. Proc Natl Acad Sci U S A 2004, 101:14216-14421.
4. Beineke A., Puff C., Seehusen F., Baumgartner W. Pathogenesis and immunopathology of systemic and nervous canine distemper. Vet Immunol Immunopathol 2009, 127:1-18.
5. Nguyen D.T., De Witte L., Ludlow M., Yüksel S., Wiesmuller K-H., Geijtenbeek T.B.H., et al. The synthetic bacterial lipopeptide Pam3CSK4 modulates respiratory syncytial virus infection independent of TLR activation. PLoS Pathog 2010, 6:e1001049.
6. Takeuchi O., Sato S., Horiuchi T., Hoshino K., Takeda K., Dong Z., et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002, 169:10-14.
7. Jin M.S., Kim S.E., Heo J.Y., Lee M.E., Kim H.M., Paik S.G., et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 2007, 130:1071-1082.
8. De Jong M.A.W.P., De Witte L., Oudhoff M.J., Gringhuis S.I., Gallay P., Geijtenbeek T.B.H. TNF-alpha and TLR agonists increase susceptibility to HIV-1 transmission by human Langerhans cells ex vivo. J Clin Invest 2008, 118:3440-3452.
9. Ogawa Y., Kawamura T., Kimura T., Ito M., Blauvelt A., Shimada S. Gram-positive bacteria enhance HIV-1 susceptibility in Langerhans cells, but not in dendritic cells, via Toll-like receptor activation. Blood 2009, 113:5157-5166.
10. Thibault S., Fromentin R., Tardif M.R., Tremblay M.J. TLR2 and TLR4 triggering exerts contrasting effects with regard to HIV-1 infection of human dendritic cells and subsequent virus transfer to CD4+ T cells. Retrovirology 2009, 6:42.
11. Silin D., Lyubomska O., Ludlow M., Duprex W.P., Rima B.K. Development of a challenge-protective vaccine concept by modifying the viral RNA-dependent RNA polymerase of canine distemper virus. J Virol 2007, 81:13649-13658.
12. Ludlow M, Nguyen DT, Silin D, Lyubomska O, De Vries RD, Von Messling V, et al. Recombinant canine distemper virus strain Snyder Hill expressing green or red fluorescent proteins causes meningoencephalitis in the ferret. J Virol 2012, doi:10.1128/JVI.06725-11.
13. Seki F., Ono N., Yamaguchi R., Yanagi Y. Efficient isolation of wild strains of canine distemper virus in Vero cells expressing canine SLAM (CD150) and their adaptability to marmoset B95a cells. J Virol 2003, 77:9943-9950.
14. Scagliarini A., Dal Pozzo F., Gallina L., Vaccari F., Morganti L. TaqMan based real time PCR for the quantification of canine distemper virus. Vet Res Commun 2007, 31(Suppl. 1):261-263.
15. De Swart R.L., Ludlow M., De Witte L., Yanagi Y., Van Amerongen G., McQuaid S., et al. Predominant infection of CD150+ lymphocytes and dendritic cells during measles virus infection of macaques. PLoS Pathog 2007, 3:e178.
16. Van Kaer L. Alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol 2005, 5:31-42.
17. Ko S.Y., Ko H.J., Chang W.S., Park S.H., Kweon M.N., Kang C.Y. Alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol 2005, 175:3309-3317.
18. Kopecky-Bromberg S.A., Fraser K.A., Pica N., Carnero E., Moran T.M., Franck R.W., et al. Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine 2009, 27:3766-3774.
19. BenMohamed L., Wechsler S.L., Nesburn A.B. Lipopeptide vaccines - yesterday, today, and tomorrow. Lancet Infect Dis 2002, 2:425-431.
20. Deres K., Schild H., Wiesmuller K.H., Jung G., Rammensee H.G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 1989, 342:561-564.
21. BenMohamed L., Gras-Masse H., Tartar A., Daubersies P., Brahimi K., Bossus M., et al. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur J Immunol 1997, 27:1242-1253.
22. Jayakumar A., Castilho T.M., Park E., Goldsmith-Pestana K., Blackwell J.M., Mahon-Pratt D. TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia). PLoS Negl Trop Dis 2011, 5:e1204.
23. Stegmann T., Kamphuis T., Meijerhof T., Goud E., De Haan A., Wilschut J. Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation. Vaccine 2010, 28:5543-5550.
24. Schultz R.D., Thiel B., Mukhtar E., Sharp P., Larson L.J. Age and long-term protective immunity in dogs and cats. J Comp Pathol 2010, 142:S102-S108.
25. Stephensen C.B., Welter J., Thaker S.R., Taylor J., Tartaglia J., Paoletti E. Canine distemper virus infection of ferrets as a model for testing morbillivirus vaccine strategies: NYVAC-and ALVAC-based CDV recombinants protect against symptomatic infection. J Virol 1997, 71:1506-1513.
26. Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375:1545-1555.
27. Collins P.L., Melero J.A. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 2011, 162:80-99.
28. Graham B.S. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 2011, 239:149-166.
29. Lemon K., De Vries R.D., Mesman A.W., McQuaid S., Van Amerongen G., Yüksel S., et al. Early target cells of measles virus after aerosol infection of non-human primates. PLoS Pathog 2011, 7:e1001263.
30. Falsey A.R., Walsh E.E., Looney R.J., Kolassa J.E., Formica M.A., Criddle M.C., et al. Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults. J Med Virol 1999, 59:221-226.
31. Falsey A.R., Singh H.K., Walsh E.E. Serum antibody decay in adults following natural respiratory syncytial virus infection. J Med Virol 2006, 78:1493-1497.